Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Observational

An Intervention to Improve the Experience of Patients in Intermediate and Long-term Care Units

NCT07926815 · tracked via the Priya Life Science Spain tracker
Phase
Observational
Started
2025-11-21
Last updated
2026-11-09

Condition(s) studied

Patient SatisfactionPatient Experience

Investigational drug(s) / intervention(s)

Patient experience intervention (problem-detection interview and multidisciplinary action plan)

Patient experience intervention (problem-detection interview and multidisciplinary action plan): Between days 10 and 15 of admission, patients (or their relatives or caregivers) are interviewed following a structured script about the negative aspects they perceive in their hospital stay, including quality of care, comfort, medical information, and assistance with daily activities. Responses are classified using the Net Promoter Score framework. The results are presented at the periodic multidisciplinary team meetings, where a personalized action plan is agreed, documented in the clinical record with assigned responsibilities and deadlines, and reassessed at approximately 30 days.

Study summary

The goal of this clinical trial is to learn if an intervention that detects and addresses the problems perceived by patients during their hospital stay can improve trust in the hospital among older patients admitted to intermediate and long-term care units. The main questions it aims to answer are:

* Does the intervention increase patients' trust in the hospital, measured as their likelihood of recommending it?
* Does the intervention reduce formal complaints, improve patients' emotional well-being, and improve the job satisfaction of nursing staff? Researchers will compare patients admitted before the intervention was introduced with patients admitted one year after it was introduced to see if trust in the hospital improves.

Participants will:

* Complete, after one month of admission, the hospital's satisfaction questionnaire (which includes the trust question) and a short emotional well-being questionnaire, either themselves or through a relative or caregiver
* In the post-intervention period, be interviewed between days 10 and 15 of admission about the negative aspects of their stay; the results are discussed at multidisciplinary team meetings, where corrective actions are agreed Nursing staff and nursing assistants on the participating wards will complete a job satisfaction questionnaire before and after the intervention.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Admitted to an intermediate or long-term care unit of Hospital Sant Antoni Abat * Length of stay of at least 1 month * Patient and/or caregiver able to take part in the study assessments * Signed informed consent, given by the patient or by the patient's legal representative Exclusion Criteria: * Cognitive or affective disorder that limits the ability to answer the study questionnaires, with no reference person available to answer on the patient's behalf * Participation in another study involving an experimental intervention during the period of this study and/or with a visit schedule incompatible with this study

Primary outcome measure(s)

  • Trust in the institution — After 1 month of admission, in the pre-intervention group and in the post-intervention group
    Score on the question "If needed, would you recommend Hospital Sant Antoni Abat?" from the hospital's inpatient satisfaction questionnaire, rated from 0 (would never recommend) to 10 (would actively recommend). Higher scores indicate greater trust. A score above 7 is considered to indicate trust in the institution.

Trial sites (1)

FacilityCityRegionStatus
Hospital Sant Antoni Abat-Consorci Sanitari Alt Penedès-Garraf Vilanova i la Geltrú Barcelona Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07926815 on ClinicalTrials.gov ↗ ← All trials in Spain